Here's a novel idea: what if you could get the hot new weight-loss drug without dealing with insurance, pharmacy benefit managers, or any of the usual healthcare bureaucracy? A venture-backed startup called Andel thinks it has the answer, and it's starting with Eli Lilly and Company's (LLY) newly approved Zepbound.

Andel just launched a direct-to-employer medication platform, backed by $4.5 million in initial funding. The whole premise is pretty simple, at least in theory: they consolidate employer demand and buy Zepbound KwikPens directly from Lilly at cash prices. Employers decide how much they want to chip in, and workers pay the rest—which, according to CEO Jay Bregman, should be less than what you'd pay through other cash channels.

The entire process—getting a prescription, paying for it, and getting next-day delivery—runs through one app. No PBM, no third-party administrator, no pre-authorization. It's a clean break from the traditional system.

So why would anyone build this? Because the current system has a pretty big gap. Roughly two-thirds of employers don't cover GLP-1s for weight loss. If they do offer coverage, there's usually no flexibility on cost. "Employers are forced to choose between zero coverage and cost overruns," Bregman said. Andel is targeting the tens of millions of workers who are currently locked out of accessing these drugs because their employer plans won't pay for them.

The interesting part is Andel's claim that pharmacy benefit managers can't just copy this model. Bregman says Andel's Zepbound product isn't available to PBMs on the reimbursement channel, calling it a "hard structural barrier." His analogy? "It's sort of like asking why taxi companies didn't build Uber. It's a totally different business model."

Lilly seems on board. Kevin Hern, Senior Vice President of Lilly Employer, called the collaboration a step toward "flexible, transparent solutions for employers." Bregman agrees, framing the model as one that expands access to new patients rather than cannibalizing existing insurance channels.

It's a clever attempt to work around a system that many find frustratingly opaque and expensive. Whether it scales or remains a niche option is the next question. But for now, it's a new path to get a drug that a lot of people really want.